Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegfilgrastim-apgf
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegfilgrastim-apgf is a biosimilar of pegfilgrastim, a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) used to reduce the risk of infection due to neutropenia in patients receiving myelosuppressive chemotherapy for cancer. It acts by stimulating the bone marrow to produce more neutrophils, thereby decreasing the duration and severity of neutropenia. Pegfilgrastim-apgf binds to the granulocyte colony-stimulating factor receptor on hematopoietic cells, activating signaling pathways that promote proliferation and differentiation of granulocyte progenitor cells. The drug is administered subcutaneously and is marketed under the brand name Nyvepria[1][3][5][8]. Developed as a biosimilar, it offers an alternative to reference pegfilgrastim products for supportive care in oncology.
- Brand names
- Nyvepria
- Other names
- HSP-130HSP130HSP 130PF-06881894PF06881894PF 06881894pegfilgrastim biosimilar
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on pegfilgrastim-apgf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegfilgrastim-apgf.